IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 66.79

Change

+1.40 (+2.14)%

Market Cap

N/A

Volume

0.11M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-02 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.89 (+1.38%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

+0.95 (+1.48%)

USD 2.50B
FXH First Trust Health Care AlphaD..

+1.20 (+1.21%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

+1.49 (+1.89%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.39 (+1.89%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

+1.39 (+1.45%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.27 (+0.90%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.74 (+2.77%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-0.42 (-0.71%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.47 (+2.46%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.63% 81% B- 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.63% 81% B- 69% C-
Trailing 12 Months  
Capital Gain 3.74% 81% B- 58% F
Dividend Return 1.01% 88% B+ 21% F
Total Return 4.76% 81% B- 50% F
Trailing 5 Years  
Capital Gain 34.59% 62% D 49% F
Dividend Return 9.14% 95% A 20% F
Total Return 43.74% 71% C- 42% F
Average Annual (5 Year Horizon)  
Capital Gain 2.97% 62% D 47% F
Dividend Return 4.35% 67% D+ 44% F
Total Return 1.38% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 14.35% 62% D 66% D+
Risk Adjusted Return 30.33% 67% D+ 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike